Manuel Cabrera
Pulmonary Disease · Bronx, NYNPI 1932271327
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,263 and has fallen 99.2% since, to $19 in 2022.
Across 281 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- GSK$1K
- AstraZeneca$744
- Novartis$461
- Insmed, Inc.$350
- Johnson & Johnson$337
- plus $1K from 21 others
What the payments were for
- Food & beverage$5,32996%
- Education$2004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 62 | $1,318 |
| GSK | 49 | $1,018 |
| AstraZeneca | 44 | $744 |
| Novartis | 29 | $461 |
| Insmed, Inc. | 14 | $350 |
| Johnson & Johnson | 16 | $337 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $226 |
| Novo Nordisk | 7 | $138 |
| Regeneron Healthcare Solutions, Inc. | 5 | $126 |
| Actelion Pharmaceuticals US, Inc. | 5 | $122 |
| Boston Scientific | 5 | $117 |
| Sanofi | 4 | $75 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Genentech USA, Inc. | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $54 |
| Pfizer | 3 | $44 |
| AbbVie(2 entities) | 2 | $41 |
| Amgen | 2 | $39 |
| Mylan Specialty L.p. | 2 | $38 |
| Circassia Inc. | 2 | $32 |
| Optinose US, Inc. | 1 | $31 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
How this compares
$5,528 in reported general payments places this provider in the 75th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Bronx
- Raji AyinlaBronx$673K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.